Effect of statins on sepsis and inflammatory factors: A Mendelian randomization study

Kai Zhang,Wei Liu,Hongjin Liang
DOI: https://doi.org/10.1111/eci.14164
2024-01-18
European Journal of Clinical Investigation
Abstract:Sepsis is critical, and there is still a lack of cost‐effective drug treatment for sepsis. We demonstrated that statins, which are inhibitors of 3‐hydroxy‐3‐methylglutaryl‐CoA reductase, can reduce the risk of sepsis through Mendelian randomization. The effect of statins on sepsis may benefit from the reduction of plasma pro‐inflammatory cytokines such as IL‐18 and CCL2. Background As inhibitors of 3‐hydroxy‐3‐methylglutaryl‐CoA reductase (HMGCR), statins can reduce the synthesis of low‐density lipoptrotein cholesterol (LDL‐C), and are clinically used as first‐line lipid‐lowering drugs to prevent cardiovascular diseases. However, the effect of statins on sepsis is controversial. Therefore, we intend to explore the effects of statins on sepsis and inflammatory factors through Mendelian randomization (MR). Method We obtained sepsis, inflammatory factors, and LDL‐C data from open and free genome‐wide association study (GWAS) for subsequent analysis. Inverse‐variance weighted (IVW) was the main method, MR‐Egger, MR‐PRESSO and Cochrane's Q‐test were used as sensitive analysis to evaluate the robustness of MR results. Results Statins were associated with a reduced risk of sepsis under 75 (sepsis in individuals under 75 years old) (OR: .716, 95% CI: .572–.896, p = .003), elevated circulating IL‐18 (OR: .762, 95% CI: .643–.903, p = .002) and elevated circulating CCL2 (OR: .416, 95% CI: .279–.620, p = 1.685e−5). Conclusion Statins may have a protective effect on sepsis and this may provide a new idea for the treatment of sepsis.
medicine, general & internal, research & experimental
What problem does this paper attempt to address?